Allergic rhinitis, Nasal polyps, Asthma prophylaxis Hypersensitivity, Immunosuppressed patients, Tuberculosis, Status asthmaticus or other acute asthma episode necessitating intensive measures, Known hypersensitivity to milk proteins or any other ingredients

Nasal Steroid Preparations

Mometasone Furoate monohydrate is a corticosteroid demonstrating antiinflammatory properties. The precise mechanism of corticosteroid action on allergic rhinitis is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell types (eg, mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (eg, histamines, eicosanoids, leukotrienes, and cytokines) involved in inflammation. Protein binding for Mometasone Furoate was reported to be 98% to 99% in concentration range of 5 to 500 ng/mL.The effective plasma elimination half life of Mometasone Furoate is 5.8 hours.

Adult Dose: Nasal Allergic rhinitis Adult: Nasal Treatment and prophylaxis of allergic rhinitis Adults: 100 mcg (2 sprays) in each nostril once daily, increased to 200 mcg into each nostril once daily if needed. Maintenance: 50 mcg in each nostril daily. In patients with a known seasonal allergen that precipitates nasal symptoms of seasonal allergic rhinitis, prophylaxis with Mometasone Nasal Spray is recommended 2 to 4 weeks prior to the anticipated start of the pollen season. Nasal polyps: 100 mcg (2 sprays) in each nostril once daily; may increase to bid after 5-6 wk if needed. Inhalation Asthma prophylaxis: Mild to moderate: Initially, 400 mcg once daily in the evening. Maintenance: 200 mcg once to bid. Severe: Initially, 400 mcg bid, then titrated to lowest effective dose once controlled. Child: Mild to moderate: Initially, 400 mcg once daily. Maintenance: 200 mcg once to bid. Severe: Initially, 400 mcg bid, then titrated to lowest effective dose once controlled. Child Dose: Nasal Allergic rhinitis Child: 2-11 yr: 50 mcg (1 spray) in each nostril daily; Child: >12 yr: 100 mcg in each nostril daily. Inhalation Asthma prophylaxis: Child: Mild to moderate: Initially, 400 mcg once daily. Maintenance: 200 mcg once to bid. Severe: Initially, 400 mcg bid, then titrated to lowest effective dose once controlled.

Increased risk of hypokalaemia with amphotericin B, potassium-wasting diuretics. Decreases hypoglycaemic effects of antidiabetic drugs. Increased serum levels with antifungals (imidazole). Increased risk of tendinopathies with fluoroquinolones.

Hypersensitivity, Immunosuppressed patients, Tuberculosis, Status asthmaticus or other acute asthma episode necessitating intensive measures, Known hypersensitivity to milk proteins or any other ingredients

>10% Headache (26%),Viral infection (14%),Pharyngitis (12%),Epistaxis (11%) 1-10% Cough (7%),Upper respiratory tract infection (6%),Dysmenorrhea (5%) Frequency Not Defined Loss of taste,Muscle soreness

There are no adequate and well-controlled studies in pregnant women. Mometasone Furoate, like other corticosteroids, should be used during pregnancy only if the potential benefits justify the potential risk to the fetus. It is not known if Mometasone Furoate is excreted in human milk. Because other corticosteroids are excreted in human milk, caution should be used when Mometasone is administered to nursing women.

Precaution: Respiratory tract tuberculosis, untreated fungal or bacterial infections, viral or parasitic infections, ocular herpes simplex Nasal septum perforation, epistaxis, wheezing Cataracts, glaucoma, increased intraocular pressure Risk of more serious or fatal course of chickenpox and measles in susceptible individuals; avoid use in unvaccinated or immunologically unexposed children or adults Deaths from adrenal insufficiency have occurred after abrupt withdrawal of oral steroids; taper withdrawal gradually May retard growth in children Immunocompromised patients Infections of nose and pharynx, including Candida albicans Excessive use may suppress hypothalamic-pituitary-adrenal function During periods of stress or severe status asthmaticus, patient may require supplementary systemic corticosteroids immediately; carry warning card to that effect Long-term administration reduces bone mineral density

There are no data available on the effects of acute or chronic overdosage with Mometasone. Because of low systemic bioavailability, and an absence of acute drugrelated systemic findings in clinical studies, overdose is unlikely to require any therapy other than observation.

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.

Mometasone depresses the formation, release and activity of endogenous inflammatory chemical mediators (e.g. kinins, histamine, liposomal enzymes and prostaglandin). It inhibits the margination and subsequent cell migration to the injury site, reverses vascular dilatation and permeability, resulting in decreased access of cells to the area of injury.